이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Viva Biotech Holdings 관리

관리 기준 확인 3/4

Viva Biotech Holdings' CEO는 Chen Cheney Mao, Jul2018 에 임명되었습니다 의 임기는 5.92 년입니다. 총 연간 보상은 CN¥ 2.39M, 60.8% 로 구성됩니다. 60.8% 급여 및 39.2% 보너스(회사 주식 및 옵션 포함). 는 HK$ 184.45M 가치에 해당하는 회사 주식의 15.66% 직접 소유합니다. 184.45M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 5.2 년입니다.

주요 정보

Chen Cheney Mao

최고 경영자

CN¥2.4m

총 보상

CEO 급여 비율	60.8%
CEO 임기	5.9yrs
CEO 소유권	15.7%
경영진 평균 재임 기간	3.2yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19

Recent updates

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 14

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21

CEO 보상 분석

Chen Cheney Mao 의 보수는 Viva Biotech Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	CN¥2m	CN¥1m	-CN¥116m
Sep 30 2023	n/a	n/a	-CN¥276m
Jun 30 2023	n/a	n/a	-CN¥436m
Mar 31 2023	n/a	n/a	-CN¥482m
Dec 31 2022	CN¥3m	CN¥1m	-CN¥528m
Sep 30 2022	n/a	n/a	-CN¥209m
Jun 30 2022	n/a	n/a	CN¥111m
Mar 31 2022	n/a	n/a	CN¥199m
Dec 31 2021	CN¥2m	CN¥1m	CN¥288m
Sep 30 2021	n/a	n/a	CN¥258m
Jun 30 2021	n/a	n/a	CN¥228m
Mar 31 2021	n/a	n/a	-CN¥79m
Dec 31 2020	CN¥1m	CN¥957k	-CN¥387m
Sep 30 2020	n/a	n/a	-CN¥349m
Jun 30 2020	n/a	n/a	-CN¥311m
Mar 31 2020	n/a	n/a	-CN¥23m
Dec 31 2019	CN¥1m	CN¥954k	CN¥266m

보상 대 시장: Chen Cheney 의 총 보상 ($USD 329.37K )은 Hong Kong 시장( $USD 233.86K ).

보상과 수익: Chen Cheney 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chen Cheney Mao (62 yo)

5.9yrs

테뉴어

CN¥2,394,000

보상

Dr. Chen Cheney Mao, Ph D has been Chairman of Viva Biotech Holdings since July 03, 2018 and served as Chief Executive Officer of Viva Biotech Holdings since July 03, 2018 until December 1, 2023. He Founde...

리더십 팀

이름	위치	테뉴어	보상	소유권
Chen Cheney Mao	Chairman & CEO	5.9yrs	CN¥2.39m	15.66% CN¥ 177.7m
Ying Wu	Executive VP & Executive Director	5.9yrs	CN¥2.68m	0.80% CN¥ 9.1m
Delin Ren	Executive Director	less than a year	CN¥3.68m	0.69% CN¥ 7.9m
Zheren Wang	Co-Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Wei Xiong	Co-Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Xueheng Cheng	Chief Technology Officer	4.8yrs	데이터 없음	데이터 없음
Zhixiong Ye	Chief Scientific Officer	5.9yrs	데이터 없음	데이터 없음
Han Dai	Chief Innovation Officer & Head of Viva BioInnovator	no data	데이터 없음	데이터 없음
Jianhua Cai	Senior Vice President	no data	데이터 없음	데이터 없음
Jianguo Ma	Senior VP & President of Shanghai Langhua Pharmaceutical	no data	데이터 없음	데이터 없음
Xianyong Bu	CBO & EVP of Viva Biotech (Shanghai)	no data	데이터 없음	데이터 없음
Rongqiang Liu	Senior Vice President	1.6yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: 1873 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chen Cheney Mao	Chairman & CEO	5.9yrs	CN¥2.39m	15.66% CN¥ 177.7m
Ying Wu	Executive VP & Executive Director	14.8yrs	CN¥2.68m	0.80% CN¥ 9.1m
Delin Ren	Executive Director	5.9yrs	CN¥3.68m	0.69% CN¥ 7.9m
Haiguang Wang	Independent Non-Executive Director	5.2yrs	CN¥225.00k	데이터 없음
Lei Fu	Independent Non-Executive Director	5.2yrs	CN¥225.00k	데이터 없음
Xiangrong Li	Independent Non-Executive Director	5.2yrs	CN¥225.00k	데이터 없음
Yuting Wu	Non-Executive Director	1.6yrs	CN¥225.00k	데이터 없음
Hui Wang	Non-Executive Director	less than a year	데이터 없음	3.97% CN¥ 45.1m

5.2yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: 1873 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.

Viva Biotech Holdings 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

Executive VP & Executive Director recently bought HK$226k worth of stock

Recent updates

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

New minor risk - Share price stability

Viva Biotech Holdings to Report Fiscal Year 2023 Results on Mar 28, 2024

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

New major risk - Revenue and earnings growth

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

New minor risk - Shareholder dilution

First half 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.048 loss in 1H 2022)

Viva Biotech Holdings to Report First Half, 2023 Results on Aug 29, 2023

Viva Biotech Holdings announced that it has received HKD 470 million in funding

Executive VP & Executive Director recently bought HK$226k worth of stock

New minor risk - Share price stability

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Full year 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.15 profit in FY 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Viva Biotech Holdings Announces Board Changes

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

First half 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.044 profit in 1H 2021)

Viva Biotech Holdings to Report First Half, 2022 Results on Aug 29, 2022

Viva Biotech Holdings Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Full year 2021 earnings: Revenues miss analyst expectations

Viva Biotech Holdings Recommend No Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Viva Biotech Holdings Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Executive VP & Executive Director recently bought HK$1.1m worth of stock

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.38 loss in 1H 2020)

Insider recently sold HK$345m worth of stock

Executive Director Fengmao Hua has left the company

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Upcoming dividend of HK$0.01 per share

Viva Biotech Holdings Recommends Final Dividend for the Year Ended December 31, 2020, Payable on or About July 9, 2021

Executive Director & CFO recently sold HK$257m worth of stock

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.19 profit in FY 2019)

Viva Biotech Holdings Provides Earnings Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings to Report Fiscal Year 2020 Results on Mar 30, 2021

Viva Biotech Holdings Reports Loss Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

New 90-day low: HK$6.90

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

New 90-day low: HK$7.27

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Viva Biotech Holdings Announces Resignation of MAO Jun as Non-Executive Director

New 90-day low: HK$7.38